STOCK TITAN
  1. Home
  2. News
  3. IBIO

iBio Inc - IBIO STOCK NEWS

Welcome to our dedicated news page for iBio (Ticker: IBIO), a resource for investors and traders seeking the latest updates and insights on iBio.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect iBio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of iBio's position in the market.

News
iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases
Rhea-AI Summary
iBio collaborates with AstralBio to develop novel antibodies for obesity and cardiometabolic conditions. The $15M PIPE financing extends cash runway through fiscal year 2025. The collaboration aims to create a diverse portfolio of best-in-class treatments using iBio's AI technology and AstralBio's expertise.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
192.17%
Tags
AI
-
News
iBio Announces $15.0 Million Private Placement
Rhea-AI Summary
iBio, Inc. (IBIO) announces a private investment in public equity financing of approximately $15.0 million, resulting in a 148% premium to the last close price. The fully subscribed PIPE financing includes investors like ADAR1 Capital Management and Lynx1 Capital Management. The Company plans to utilize the funds for general corporate purposes, research and development, and working capital, extending its cash runway through fiscal year 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
192.17%
Tags
none
-
News
iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka
Rhea-AI Summary
iBio, Inc. (IBIO) announces a strategic asset purchase agreement with Otsuka Pharmaceutical Co., Ltd., involving an upfront payment of $1 million and potential future milestone payments of up to $52.5 million. The deal focuses on iBio's early-stage PD-1 agonist program, enhancing its immuno-oncology pipeline. PD-1 agonists play a crucial role in immune system modulation, offering promising therapeutic potential for autoimmune diseases. The transaction aims to provide iBio with significant non-dilutive capital, validate its technology stack, and enable a focused approach on immuno-oncology and AI-based drug discovery.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.83%
Tags
none
News
iBio Announces Participation in 23rd Annual PepTalk Conference
Rhea-AI Summary
iBio, Inc. (NYSEA:IBIO) announced that its VP of Platform Technologies, Matt Greving, will give a presentation at the 23rd annual PepTalk Conference on enhancing bispecific T-cell engager discovery and development with machine learning. He will discuss how iBio's technology stack potentially overcomes challenges in the discovery of bispecific T-Cell Engagers for cancer immunotherapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.56%
Tags
none
-
News
iBio Amends and Extends Maturity of Credit Agreement
Rhea-AI Summary
iBio, Inc. (NYSEA:IBIO) extends maturity date of Credit Agreement to March 29, 2024, providing more time for planned divestiture of legacy CDMO business. The amendment with Woodforest National Bank allows financial flexibility for the sale of the biologics manufacturing facility in Texas and advancement of AI drug discovery platform and immunotherapy pipeline.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.44%
Tags
none
-
News
iBio, Inc. Announces Pricing of $4.5 Million Public Offering
Rhea-AI Summary
iBio, Inc. (NYSEA:IBIO) announced a public offering of 2,250,000 shares of common stock and accompanying Series C and Series D warrants, resulting in gross proceeds of approximately $4.5 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-50%
Tags
offering
News
iBio Announces Reverse Stock Split
Rhea-AI Summary
iBio, Inc. (IBIO) has approved a 20-to-1 reverse split of its common stock, effective on November 29, 2023. The reverse stock split will result in every 20 shares being combined into one share, reducing the outstanding shares from 28,100,733 to 1,405,036. The split will not affect ownership percentage except for holders of fractional shares. The exercise prices of stock options, warrants, and equity incentive plans will be adjusted accordingly.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-31.03%
Tags
none
-
News
iBio Further Expands Tech Stack with ShieldTx™; Enhances Immuno-Oncology Development Pipeline with Conditionally Activated MUC16xCD3 Bispecific
Rhea-AI Summary
iBio, Inc. has announced the launch of ShieldTx, an AI-powered antibody masking technology that enables targeted delivery to diseased tissue. The technology aims to overcome challenges in complex targets, safety, and developability in antibody discovery and development. iBio used ShieldTx to develop masks for its MUC16-targeted bispecific antibody candidates. The technology deactivates the antibodies until they encounter a specific enzyme in the target tissue, reducing off-tissue side effects and enhancing therapeutic safety. ShieldTx can be applied to cancer therapeutics and autoimmune and inflammatory diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.85%
Tags
none
-
News
iBio to Highlight Technology for Advancing Discovery of Bispecifics at Festival of Biologics
Rhea-AI Summary
iBio's VP of Platform Technologies to present on enhancing T-cell engagers at the Festival of Biologics
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.14%
Tags
none
News
iBio Explains Recent Filing of Registration Statement
Rhea-AI Summary
iBio clarifies its post-effective amendment to its Form S-3 on Form S-1, maintaining the registration of common stock warrants issued and outstanding. No new securities are being registered.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.33%
Tags
none
Stock IBIO logo
iBio Inc

NYSE:IBIO

IBIO Rankings

#5258 Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

IBIO Stock Data

17.20M
1.25M
0.18%
26.9%
4.64%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Bryan

About IBIO

ibio is a contract development and manufacturing organization equipped to take clients from the early stages of product selection through regulatory approval and commercial product launch. ibio’s technology platform and facility capabilities are applicable to the development of biotherapeutics, vaccines, diagnostic products, and certain types of medical devices – and often provide significant time and value advantages over traditional approaches. ibio’s lab to launch capabilities assure the most rapid manufacturing support to reach the clinic. ibio’s team is comprised of knowledgeable protein scientists, microbiologists and manufacturing and regulatory experts, all of whom add significant expertise and value throughout the entire process. the same team and facility that produces preclinical and clinical material will be the same team producing your product for market launch; contributing to the seamless scale-up process the ibio technology platform creates.